• Tue news: Pfizer explores sale of hospital drugs unit. FDA declines full approval of Ocaliva. AZ better than expected Q3 results. Pfizer, Lilly telehealth platforms draw scrutiny. 23andMe cutting lays off 40%. See more on our front page

Merck looks to ditch the needles with its next-gen oral PCSK9 inhibitor for high cholesterol

Quote
cafead

cafead

Administrator
Staff member
  • cafead   Nov 15, 2021 at 11:02: AM
via The pharma giant unveiled on Monday what it says are the first in-human results for an oral PCSK9 inhibitor. The candidate, MK-0616, was well-tolerated in men and women with high cholesterol at doses up to 300 mg, with no deaths or serious side effects, the company said at the American Heart Association conference.

article source
 




Top Bottom
Back
Quote